Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11510524 | 0.91 | OPRK1 (0.48) | ALDH1A1TSHR | |
| SCHEMBL20349553 | 0.83 | TRPA1 (0.49) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL23423397 | 0.82 | CHRNB2 (0.59) | DRD2 | |
| SCHEMBL23032150 | 0.82 | CHRNB2 (0.59) | DRD2 | |
| SCHEMBL13407277 | 0.82 | CHRNB2 (0.59) | DRD2 | |
| SCHEMBL19275748 | 0.81 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAGAAMAPT | |
| SCHEMBL18862021 | 0.80 | OPRK1 (0.52) | DRD2ALDH1A1 | |
| SCHEMBL13842760 | 0.79 | HRH3 (0.46) | KDM4EALDH1A1LMNAGAAMAPT | |
| SCHEMBL23064641 | 0.79 | DRD2 (0.54) | DRD2KDM4EALDH1A1GAATSHR | |
| SCHEMBL4949268 | 0.78 | CFB (0.36) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | DRD2 1040/4885KDM4E 3486/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.